600267 Zhejiang Hisun Pharmaceutical Co.,Ltd.
Closed 11-06 15:00:00
13.40
-0.43
-3.11%
High13.68Low13.25Vol32.59M
Open13.38D1 Closing13.83Amplitude3.11%
Mkt Cap15.81BTradable Cap15.81BTotal Shares1.18B
T/O438.00MT/O Rate2.76%Tradable Shares1.18B
P/B1.66ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Hisun Pharmaceutical's Shareholder Completes 751 Million Yuan Transfer of Company Stake
MT Newswires Live  ·  11-05 14:01
Hisun Pharmaceutical's Shareholder Completes 751 Million Yuan Transfer of Company Stake
Zhejiang Hisun Pharmaceutical Reports First Three Quarters Results with Net Profit Attributable to Parent of 1.146 Billion Yuan, Up 148.56% Year-on-Year
Stock News  ·  10-28
Zhejiang Hisun Pharmaceutical Reports First Three Quarters Results with Net Profit Attributable to Parent of 1.146 Billion Yuan, Up 148.56% Year-on-Year
Zhejiang Hisun Pharmaceutical Says Upfront Payment 10 Mln Yuan, Development Milestone Payments up to 348 Mln Yuan, Sales Milestone Payments up to 630 Mln Yuan
THOMSON REUTERS  ·  10-27
Zhejiang Hisun Pharmaceutical Says Upfront Payment 10 Mln Yuan, Development Milestone Payments up to 348 Mln Yuan, Sales Milestone Payments up to 630 Mln Yuan
Zhejiang Hisun Pharmaceutical Says it Plans to Acquire Global Rights to Rigerna Therapeutics's Small Nucleic Acid Tech Platform and Rgn6669 Product
THOMSON REUTERS  ·  10-27
Zhejiang Hisun Pharmaceutical Says it Plans to Acquire Global Rights to Rigerna Therapeutics's Small Nucleic Acid Tech Platform and Rgn6669 Product
Zhejiang Hisun Pharmaceutical Q3 Net Profit up 214.6% Y/Y
THOMSON REUTERS  ·  10-27
Zhejiang Hisun Pharmaceutical Q3 Net Profit up 214.6% Y/Y
Zhejiang Hisun Pharmaceutical Sees 9-Month Net Profit up 149.46% Y/Y
Reuters  ·  10-16
Zhejiang Hisun Pharmaceutical Sees 9-Month Net Profit up 149.46% Y/Y
Hisun Pharmaceutical's Subsidiary Gets Nod for Topical Solution for Cat Infection
MT Newswires Live  ·  09-15
Hisun Pharmaceutical's Subsidiary Gets Nod for Topical Solution for Cat Infection
FDA Allows Hisun Pharmaceutical's Glucosamine Hydrochloride in US Market
MT Newswires Live  ·  09-14
FDA Allows Hisun Pharmaceutical's Glucosamine Hydrochloride in US Market
Hisun Charts New Course at BIOHK2026: Embracing Biomanufacturing and Expanding into Wellness Markets
Deep News  ·  09-14
Hisun Charts New Course at BIOHK2026: Embracing Biomanufacturing and Expanding into Wellness Markets
Hisun's Subsidiary Secures US Self-GRAS Approval for Glucosamine Hydrochloride
Stock News  ·  09-11
Hisun's Subsidiary Secures US Self-GRAS Approval for Glucosamine Hydrochloride
Zhejiang Hisun Pharmaceutical Subsidiary Gets China Nod for Anti-Parasite Drug for Cats
MT Newswires Live  ·  09-08
Zhejiang Hisun Pharmaceutical Subsidiary Gets China Nod for Anti-Parasite Drug for Cats
Zhejiang Hisun Pharmaceutical Schedules Investor Meeting for First-Half 2026 Financial Results
Deep News  ·  08-25
Zhejiang Hisun Pharmaceutical Schedules Investor Meeting for First-Half 2026 Financial Results
Zhejiang Hisun Pharmaceutical H1 Net Profit up 112.8% Y/Y
Reuters  ·  08-25
Zhejiang Hisun Pharmaceutical H1 Net Profit up 112.8% Y/Y
Zhejiang Hisun Pharmaceutical Wins Pre-Bids for Five Drugs Under China Procurement System
MT Newswires Live  ·  08-04
Zhejiang Hisun Pharmaceutical Wins Pre-Bids for Five Drugs Under China Procurement System
Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement
Stock News  ·  08-03
Zhejiang Hisun Pharmaceutical Secures Tentative Selection for Five Products in National Bulk Drug Procurement
Zhejiang Hisun Pharmaceutical Receives US FDA Abbreviated New Drug Application Approval for Leukemia Injection
MT Newswires Live  ·  07-27
Zhejiang Hisun Pharmaceutical Receives US FDA Abbreviated New Drug Application Approval for Leukemia Injection
Zhejiang Hisun Pharmaceutical Subsidiary Obtains US FDA Clearance for Generic Cancer Drug Injection
Stock News  ·  07-24
Zhejiang Hisun Pharmaceutical Subsidiary Obtains US FDA Clearance for Generic Cancer Drug Injection
Zhejiang Hisun Pharmaceutical Sees H1 Net Profit up 100.62%-117.34% Y/Y
THOMSON REUTERS  ·  07-10
Zhejiang Hisun Pharmaceutical Sees H1 Net Profit up 100.62%-117.34% Y/Y
Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication
MT Newswires Live  ·  06-30
Zhejiang Hisun Pharmaceutical Gets Approval for Cytomegalovirus Medication
Zhejiang Hisun Pharmaceutical Receives Approval for Letermovir Active Ingredient
Stock News  ·  06-29
Zhejiang Hisun Pharmaceutical Receives Approval for Letermovir Active Ingredient

Introduction

Company Name.
浙江海正药业股份有限公司
Industry:
医药制造业
Listing Date:
2000-07-25
Main Business:
　　浙江海正药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是海博麦布片（赛斯美）、注射用哌拉西林钠他唑巴坦钠（特治星）、盐酸米诺环素胶囊（玫满）、茚达特罗格隆溴铵吸入粉雾剂（杰润）、注射用丝裂霉素、瑞舒伐他汀钙片（海舒严）、注射用亚胺培南西司他丁钠（俊特）、米尔贝肟吡喹酮片（海乐妙）、丁二磺酸腺苷蛋氨酸肠溶片（喜美欣）、英夫马芬净。
Issue price:
11.83